NASDAQ:ARQT
Arcutis Biotherapeutics, Inc.
- Stock
Last Close
10.10
26/07 20:00
Market Cap
1.14B
Beta: 0.45
Volume Today
1.46M
Avg: 993.92K
PE Ratio
−1.36
PFCF: −2.77
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | -255K - | 335K 231.37% | 4.35M 1,197.61% | 10.32M 137.50% | ||||
average payables | 1.17M - | 1.60M 37.13% | 4.27M 166.53% | 7.25M 69.61% | 8.09M 11.64% | 10.41M 28.67% | ||
average receivables | 255K - | 436K 70.98% | 4.41M 911.47% | 17.13M 288.49% | ||||
book value per share | -0.28 - | -1.33 380.41% | -1.85 39.44% | 7.59 509.11% | 6.03 20.59% | 3.81 36.79% | 0.00 99.97% | |
capex per share | -0.01 - | -0.01 6.97% | -0.02 123.78% | -0.42 2,000.75% | -0.00 100.00% | |||
capex to depreciation | -1.51 - | -2.63 73.92% | -2.19 16.70% | -24.93 1,037.43% | -0.28 98.87% | |||
capex to operating cash flow | 0.01 - | 0.00 58.76% | 0.01 100.64% | 0.09 1,485.58% | 0.00 98.08% | |||
capex to revenue | -6.32 - | -0.01 99.89% | ||||||
cash per share | 0.19 - | 2.82 1,390.35% | 2.89 2.25% | 7.97 176.13% | 7.83 1.76% | 7.44 5.00% | 0.00 99.95% | |
days of inventory on hand | 3.64K - | 961.28 73.57% | ||||||
days payables outstanding | 4.27K - | 877.70 79.46% | ||||||
days sales outstanding | 837.54 - | 158.03 81.13% | ||||||
debt to assets | 0.00 - | 0.02 480.12% | 0.19 1,041.76% | 0.45 137.25% | 0.60 33.80% | |||
debt to equity | -0.00 - | 0.02 488.54% | 0.26 1,320.38% | 0.97 270.93% | 2.32 140.30% | |||
dividend yield | ||||||||
earnings yield | -0.01 - | -0.05 286.80% | -0.05 12.18% | -0.14 146.14% | -0.20 48.60% | -0.39 96.31% | -0.00 99.70% | |
enterprise value | 389.75M - | 353.78M 9.23% | 701.38M 98.25% | 943.23M 34.48% | 1.01B 6.63% | 963.38M 4.22% | 223.97B 23,148.81% | |
enterprise value over ebitda | -94.92 - | -17.93 81.11% | -16.33 8.88% | -6.91 57.70% | -4.87 29.51% | -3.26 33.12% | -928.96 28,423.88% | |
ev to operating cash flow | -103.25 - | -25.12 75.67% | -16.37 34.81% | -8.34 49.04% | -5.76 30.98% | -3.74 35.10% | -906.57 24,151.76% | |
ev to sales | 261.36 - | 3.76K 1,337.69% | ||||||
free cash flow per share | -0.21 - | -0.78 273.11% | -1.23 57.50% | -3.18 158.36% | -3.55 11.85% | -5.11 43.64% | -0.00 99.93% | |
free cash flow yield | -0.01 - | -0.04 273.11% | -0.06 57.50% | -0.11 100.23% | -0.17 51.71% | -0.35 101.29% | -0.00 99.68% | |
graham net net | -0.30 - | -1.34 347.63% | -2.02 50.77% | 7.20 456.86% | 5.62 22.04% | 3.27 41.76% | 0.00 99.98% | |
graham number | 1.31 - | 5.65 331.07% | 7.07 25.07% | 25.48 260.47% | 23.77 6.72% | 22.37 5.90% | 0.01 99.95% | |
income quality | 0.76 - | 0.73 3.54% | 1.02 39.44% | 0.83 18.32% | 0.85 1.58% | 0.83 2.22% | 0.94 13.90% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0.02 Infinity% | 0.02 17.88% | |
interest coverage | -19.27 - | 8.11 142.11% | ||||||
interest debt per share | 0.01 - | 0.14 1,489.57% | 1.57 1,027.96% | 3.96 152.57% | 0.00 99.94% | |||
inventory turnover | 0.10 - | 0.38 278.39% | ||||||
invested capital | -0.00 - | 0.02 488.54% | 0.26 1,320.38% | 0.97 270.93% | 2.32 140.30% | |||
market cap | 393.17M - | 393.17M 0% | 764.40M 94.42% | 1.00B 31.26% | 1.02B 2.13% | 814.48M 20.51% | 223.86B 27,384.70% | |
net current asset value | -4.99M - | -23.99M 380.41% | -65.57M 173.34% | 265.18M 504.44% | 292.30M 10.23% | 197.71M 32.36% | 77.73M 60.68% | |
net debt to ebitda | 0.83 - | 2.00 139.79% | 1.47 26.46% | 0.44 70.00% | 0.09 79.23% | -0.50 650.30% | -0.49 3.17% | |
net income per share | -0.28 - | -1.07 286.80% | -1.20 12.18% | -3.80 217.61% | -4.17 9.56% | -5.84 40.09% | -0.00 99.94% | |
operating cash flow per share | -0.21 - | -0.78 273.11% | -1.22 56.43% | -3.17 159.41% | -3.53 11.53% | -4.68 32.49% | -0.00 99.92% | |
payables turnover | 0.09 - | 0.42 386.84% | ||||||
receivables turnover | 0.44 - | 2.31 429.99% | ||||||
research and ddevelopement to revenue | 49.49 - | 1.86 96.25% | ||||||
return on tangible assets | -1.30 - | -0.38 71.09% | -0.39 4.14% | -0.45 15.91% | -0.50 10.90% | -0.73 44.06% | -0.78 7.69% | |
revenue per share | 0.07 - | 0.00 98.72% | ||||||
roe | 1.00 - | 0.80 19.49% | 0.65 19.55% | -0.50 177.63% | -0.69 37.96% | -1.53 121.63% | -2.96 92.85% | |
roic | 0.82 - | 0.80 2.45% | 0.67 16.53% | -0.49 172.74% | -0.54 11.21% | -0.75 37.78% | -0.82 9.45% | |
sales general and administrative to revenue | ||||||||
shareholders equity per share | -0.28 - | -1.33 380.41% | -1.85 39.44% | 7.59 509.11% | 6.03 20.59% | 3.81 36.79% | 0.00 99.97% | |
stock based compensation to revenue | 8.87 - | 0.65 92.66% | ||||||
tangible asset value | -4.99M - | -23.99M 380.41% | -65.03M 171.10% | 270.62M 516.15% | 297.68M 10.00% | 202.39M 32.01% | 82.23M 59.37% | |
tangible book value per share | -0.28 - | -1.33 380.41% | -1.85 39.44% | 7.59 509.11% | 6.03 20.59% | 3.68 38.96% | 0.00 99.97% | |
working capital | 3.13M - | 48.42M 1,448.61% | 101.24M 109.06% | 270.22M 166.92% | 369.45M 36.72% | 399.60M 8.16% | 283.76M 28.99% |
All numbers in USD (except ratios and percentages)